Hematopoietic malignancies associated with viral and alcoholic hepatitis

Cancer Epidemiology Biomarkers and Prevention

Volumn 17, Issue 11, 2008, Pages 3069-3075

  Anderson, Lesley A ^a,b   Pfeiffer, Ruth ^a   Warren, Joan L ^a   Landgren, Ola ^a   Gadalla, Shahinaz ^a   Berndt, Sonja I ^a   Ricker, Winnie ^c   Parsons, Ruth ^c   Wheeler, William ^c   Engels, Eric A ^a  

^a NATIONAL CANCER INSTITUTE   (United States)

^b QUEEN'S UNIVERSITY BELFAST   (United Kingdom)

^c INFORMATION MANAGEMENT SERVICES INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACUTE GRANULOCYTIC LEUKEMIA; AGED; ALCOHOL LIVER DISEASE; ARTICLE; B CELL LYMPHOMA; BURKITT LYMPHOMA; CANCER RISK; CONTROLLED STUDY; FEMALE; FOLLICULAR LYMPHOMA; HEMATOLOGIC MALIGNANCY; HEPATITIS B; HEPATITIS C; HUMAN; LOGISTIC REGRESSION ANALYSIS; LYMPHOPROLIFERATIVE DISEASE; MAJOR CLINICAL STUDY; MALE; NONHODGKIN LYMPHOMA; POPULATION BASED CASE CONTROL STUDY; PREVALENCE; PRIORITY JOURNAL; VIRUS HEPATITIS;

AGED; AGED, 80 AND OVER; CASE-CONTROL STUDIES; FEMALE; HEMATOLOGIC NEOPLASMS; HEPATITIS B; HEPATITIS C; HEPATITIS, ALCOHOLIC; HUMANS; LOGISTIC MODELS; MALE; PREVALENCE; SEER PROGRAM; UNITED STATES;

EID: 55849090313     PISSN: 10559965     EISSN: None     Source Type: Journal    
DOI: 10.1158/1055-9965.EPI-08-0408     Document Type: Article

References (49)

1. Engels EA. Infectious agents as causes of non-Hodgkin lymphoma. Cancer Epidemiol Biomarkers Prev 2007;16:401-4.
2. Matsuo K, Kusano A, Sugumar A, Nakamura S, Tajima K, Mueller NE. Effect of hepatitis C virus infection on the risk of non-Hodgkin's lymphoma: a meta-analysis of epidemiological studies. Cancer Sci 2004;95:745-52.
3. Dal ML, Franceschi S. Hepatitis C virus and risk of lymphoma and other lymphoid neoplasms: a meta-analysis of epidemiologic studies. Cancer Epidemiol Biomarkers Prev 2006;15:2078-85.
4. Dammacco F, Sansonno D, Piccoli C, Tucci FA, Racanelli V. The cryoglobulins: an overview. Eur J Clin Invest 2001;31:628-38.
5. Morton LM, Engels EA, Holford TR, et al. Hepatitis C virus and risk of non-Hodgkin lymphoma: a population-based case-control study among Connecticut women. Cancer Epidemiol Biomarkers Prev 2004;13:425-30.
6. Giordano TP, Henderson L, Landgren O, et al. Risk of non-Hodgkin lymphoma and lymphoproliferative precursor diseases in US veterans with hepatitis C virus. JAMA 2007;297:2010-7.
7. de Sanjose S, Benavente Y, Vajdic CM, et al. Hepatitis C and non-Hodgkin lymphoma among 4,784 cases and 6,269 controls from the InterLymph Consortium. Clinical Gastroenterol Hepatol 2008;6: 451-8.
8. Landgren O, Gridley G, Check D, Caporaso NE, Morris BL. Acquired immune-related and inflammatory conditions and subsequent chronic lymphocytic leukaemia. Br J Haematol 2007;139:791-8.
9. Brown LM, Gridley G, Check D, Landgren O. Risk of multiple myeloma and monoclonal gammopathy of undetermined significance among White and Black male United States veterans with prior autoimmune, infectious, inflammatory, and allergic disorders. Blood 2008;111:3388-94.
10. Duberg AS, Nordstrom M, Torner A, et al. Non-Hodgkin's lymphoma and other nonhepatic malignancies in Swedish patients with hepatitis C virus infection. Hepatology 2005;41:652-9.
11. Bianco E, Marcucci F, Mele A, et al. Prevalence of hepatitis C virus infection in lymphoproliferative diseases other than B-cell non-Hodgkin's lymphoma, and in myeloproliferative diseases: an Italian Multi-Center case-control study. Haematologica 2004;89:70-6.
12. Gentile G, Mele A, Monarco B, et al. Hepatitis B and C viruses, human T-cell lymphotropic virus types I and II, leukemias: a case-control study. The Italian Leukemia Study Group. Cancer Epidemiol Biomarkers Prev 1996;5:227-30.
13. Montella M, Crispo A, de Bellis G, et al. HCV and cancer: a case-control study in a high-endemic area. Liver 2001;21:335-41.
14. Cucuianu A, Patiu M, Duma M, et al. Hepatitis B and C virus infection in Romanian non-Hodgkin's lymphoma patients. Br J Haematol 1999;107:353-6.
15. Kim JH, Bang YJ, Park BJ, et al. Hepatitis B virus infection and B-cell non-Hodgkin's lymphoma in a hepatitis B endemic area: a case-control study. Jpn J Cancer Res 2002;93:471-7.
16. Kuniyoshi M, Nakamuta M, Sakai H, et al. Prevalence of hepatitis B or C virus infections in patients with non-Hodgkin's lymphoma. J Gastroenterol Hepatol 2001;16:215-9.
17. Lim ST, Fei G, Quek R, et al. The relationship of hepatitis B virus infection and non-Hodgkin's lymphoma and its impact on clinical characteristics and prognosis. Eur J Haematol 2007;79:132-7.
18. Marcucci F, Mele A, Spada E, et al. High prevalence of hepatitis B virus infection in B-cell non-Hodgkin's lymphoma. Haematologica 2006;91:554-7.
19. Takai S, Tsurumi H, Ando K, et al. Prevalence of hepatitis B and C virus infection in haematological malignancies and liver injury following chemotherapy. Eur J Haematol 2005;74:158-65.
20. Ulcickas YM, Quesenberry CP, Jr., Guo D, et al. Incidence of non-Hodgkin's lymphoma among individuals with chronic hepatitis B virus infection. Hepatology 2007;46:107-12.
21. Wang F, Xu RH, Han B, et al. High incidence of hepatitis B virus infection in B-cell subtype non-Hodgkin lymphoma compared with other cancers. Cancer 2007;109:1360-4.
22. Amin J, Dore GJ, O'Connell DL, et al. Cancer incidence in people with hepatitis B or C infection: a large community-based linkage study. J Hepatol 2006;45:197-203.
23. Bautista AP. Neutrophilic infiltration in alcoholic hepatitis. Alcohol 2002;27:17-21.
24. Alter MJ. Hepatitis C virus infection in the United States. J Hepatol 1999;31 Suppl 1:88-91.
25. McQuillan GM, Coleman PJ, Kruszon-Moran D, Moyer LA, Lambert SB, Margolis HS. Prevalence of hepatitis B virus infection in the United States: the National Health and Nutrition Examination Surveys, 1976 through 1994. Am J Public Health 1999;89:14-8.
26. Warren JL, Klabunde CN, Schrag D, Bach PB, Riley GF. Overview of the SEER-Medicare data: content, research applications, and generalizability to the United States elderly population. Med Care 2002;40:IV-18.
27. Jaffe ES, Harris NL, Stein H, Vardiman JW. Pathology and Genetics of Tumours of Hematopoietic and Lymphoid Tissues. World Health Organization Classification of Tumours. Lyon: IARC; 2001.
28. Morton LM, Turner JJ, Cerhan JR, et al. Proposed classification of lymphoid neoplasms for epidemiologic research from the Pathology Working Group of the International Lymphoma Epidemiology Consortium (InterLymph). Blood 2007;110:695-708.
29. Fritz A, Percy C, Jack A, Sobin LH, Parkin MD. International Classification of Diseases for Oncology, 3rd ed. 2000.
30. Kuroda J, Omoto A, Fujiki H, et al. Primary hepatic Burkitt's lymphoma with chronic hepatitis C. Acta Haematol 2001;105:237-40.
31. Ascoli V, Lo CF, Artini M, Levrero M, Fruscalzo A, Mecucci C. Primary effusion Burkitt's lymphoma with t(8;22) in a patient with hepatitis C virus-related cirrhosis. Hum Pathol 1997;28:101-4.
32. de Sanjose S, Nieters A, Goedert JJ, et al. Role of hepatitis C virus infection in malignant lymphoma in Spain. Int J Cancer 2004;111:81-5.
33. Rosa D, Saletti G, de Gregorio E, et al. Activation of naive B lymphocytes via CD81, a pathogenetic mechanism for hepatitis C virus-associated B lymphocyte disorders. Proc Natl Acad Sci U S A 2005;102:18544-9.
34. Pileri P, Uematsu Y, Campagnoli S, et al. Binding of hepatitis C virus to CD81. Science 1998;282:938-41.
35. Monni O, Franssila K, Joensuu H, Knuutila S. BCL2 overexpression in diffuse large B-cell lymphoma. Leuk Lymphoma 1999;34:45-52.
36. Zignego AL, Ferri C, Giannini C, et al. Hepatitis C virus infection in mixed cryoglobulinemia and B-cell non-Hodgkin's lymphoma: evidence for a pathogenetic role. Arch Virol 1997;142:545-55.
37. Hermine O, Lefrere F, Bronowicki JP, et al. Regression of splenic lymphoma with villous lymphocytes after treatment of hepatitis C virus infection. N Engl J Med 2002;347:89-94.
38. Yamasaki R, Yokota K, Okada H, et al. Immune response in Helicobacter pylori-induced low-grade gastric-mucosa-associated lymphoid tissue (MALT) lymphoma. J Med Microbiol 2004;53:21-9.
39. Delforge M. Understanding the pathogenesis of myelodysplastic syndromes. Hematol J 2003;4:303-9.
40. Sansonno D, Lotesoriere C, Cornacchiulo V, et al. Hepatitis C virus infection involves CD34(+) hematopoietic progenitor cells in hepatitis C virus chronic carriers. Blood 1998;92:3328-37.
41. Musolino C, Campo S, Pollicino T, Squadrito G, Spatari G, Raimondo G. Evaluation of hepatitis B and C virus infections in patients with non-Hodgkin's lymphoma and without liver disease. Haematologica 1996;81:162-4.
42. Tsutsumi Y, Kanamori H, Mori A, et al. Reactivation of hepatitis B virus with rituximab. Expert Opin Drug Saf 2005;4:599-608.
43. Ozguroglu M, Bilici A, Turna H, Serdengecti S. Reactivation of hepatitis B virus infection with cytotoxic therapy in non-Hodgkin's lymphoma. Med Oncol 2004;21:67-72.
44. Lok AS, Liang RH, Chiu EK, Wong KL, Chan TK, Todd D. Reactivation of hepatitis B virus replication in patients receiving cytotoxic therapy. Report of a prospective study. Gastroenterology 1991;100:182-8.
45. Morton LM, Zheng T, Holford TR, et al. Alcohol consumption and risk of non-Hodgkin lymphoma: a pooled analysis. Lancet Oncol 2005;6:469-76.
46. Chiu BC, Cerhan JR, Gapstur SM, et al. Alcohol consumption and non-Hodgkin lymphoma in a cohort of older women. Br J Cancer 1999;80:1476-82.
47. Diaz LE, Montero A, Gonzalez-Gross M, Vallejo AI, Romeo J, Marcos A. Influence of alcohol consumption on immunological status: a review. Eur J Clin Nutr 2002;56 Suppl 3:S50-3.
48. Engels EA, Pfeiffer RM, Goedert JJ, et al. Trends in cancer risk among people with AIDS in the United States 1980-2002. AIDS 2006;20:1645-54.
49. Ries LAG, Melbert D, Krapcho M, et al. SEER Cancer Statistics Review, 1975-2004, National Cancer Institute, Bethesda, MD, http://seer.cancer.gov/csr/ 1975_2004 based on November 2006 SEER data submission, posted to the SEER website, 2007.